10x Genomics CEO Calls NIH The 'Foundational Jewel' Of Biomedical Progress, Says 40% To 50% Of Revenue Supported By Academic And Government Research Funding

What will U.S.-China trade talks achieve? How will Trump's tariffs affect U.S. consumers? Why did Lyft's stock surge 20% today? What impact does the U.S.-UK trade deal have? Why did Krispy Kreme stock drop sharply? How are tech stocks responding to tariff concerns? What caused Bitcoin to surge above $100,000? Why is the SEC critical of Ripple settlement? How will Panasonic's job cuts affect the market?

10x Genomics CEO Calls NIH The 'Foundational Jewel' Of Biomedical Progress, Says 40% To 50% Of Revenue Supported By Academic And Government Research Funding — Pulls Full Year Revenue Guidance

benzinga.com/general/health-care/25/05/45310176/10x-genomics-ceo-calls-nih-the-foundational-jewel-of-biomedical-progress-says-40-to-50-of-rev

During its first-quarter earnings call on Thursday, 10x Genomics Inc. (NASDAQ:TXG) withdrew its full-year guidance, opting instead to provide quarterly forecasts.
What Happened: The company cited policy uncertainty stemming from recent U.S. government budget cuts for academic research…

This story appeared on benzinga.com, 2025-05-09 06:37:54.